Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Inclusion Criteria

• •Subjects must have histologically confirmed diagnosis of non-Hodgkin?s lymphoma that has relapsed, or is refractory, after upfront induction therapy. Excluded histologies are T-cell lymphomas, post-transplant lymphoproliferative disorder, Burkitt lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma. All other histologies are eligible that include but not limited to: diffuse-large B-cell lymphoma, follicular lymphoma (grades I, II, and III), marginal zone lymphoma, transformed indolent lymphoma, grey zone lymphoma, and undifferentiated B-cell lymphoma. Patients with non-Hodgkin's lymphoma (NHL) who are at high risk of relapse can be enrolled in sustained partial response (PR) after induction chemotherapy (PR1)
• •Expected survival of more than six months
• •Karnofsky performance status \>= 80%
• •Within 1 week prior to initiation of treatment: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \< 3 x upper limits of normal (ULN) unless due to disease
• •Within 1 week prior to initiation of treatment: Total bilirubin \< 2 x ULN unless due to disease
• •Within 1 week prior to initiation of treatment: Calculated glomerular filtration rate (GFR) 30 ml/min
• •Within 1 week prior to initiation of treatment: Absolute neutrophil count (ANC) \> 500 cells/mm\^3
• •Within 1 week prior to initiation of treatment: Platelet count \> 50 mm\^3
• •Left ventricular ejection fraction \>= 40%
• •Diffusion capacity of carbon monoxide (DLCO) \>= 50% predicted
• •Ability to collect 2 x 10\^6/kg CD34+ cells for transplantation
• •Patient must be otherwise eligible for autologous stem cell transplantation (ASCT) per local institutional guidelines
• •No serious disease, or condition, that, in the opinion of the investigator, would compromise the patient?s ability to participate in the study
• •Subjects must have the ability to understand and the willingness to sign a written informed consent document